Oghenekome Gbinigie

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 391 citations · Full text

Long Covid, Treatment And Prevention, Covid-19 Pandemic +9

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Jienchi Dorward, Ly‐Mee Yu et al. · The Lancet · 2021 · 306 citations · Full text

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al. · The Lancet · 2021 · 302 citations · Full text

Epidemiology, Respiratory Diseases, Medicine +6

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Ly‐Mee Yu, Jienchi Dorward et al. · The Lancet Respiratory Medicine · 2021 · 77 citations · Full text

Preventive Medicine, Treatment And Prevention, Medicine +9

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · SSRN Electronic Journal · 2022 · 50 citations · Full text